RheumNow Podcast - ACR 2021 Rehash (the good stuff..)
Nov 12, 2021
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Read Article
Herpes Zoster and Rheumatoid Arthritis: Dr. Akhil Sood ( @AkhilSoodMD) reviews abstract #0981 presented at the #ACR21 annual meeting.https://t.co/M95XQOBWVf https://t.co/X9vaAEAias
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 19, 2021
Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kayhttps://t.co/GtMtUh33QE https://t.co/yjJngF25Y4
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 12, 2021
Day 4 Report from ACR21
Nov 10, 2021
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
Read Article
ACR21 – Day 3 Report
Nov 09, 2021
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Read Article
Did you know?🤔Immune #aging:
🔖Begins at 20y and accelerates at 50y
🔖Species-specific
🔖The older immune system is restructured (keep that in mind when diagnosing or treating these pts)
🔖Accelerated w/ chemotx, chronic infection etc.
@RheumNow #ACR21 https://t.co/bgbN3VKMCw
sheila @RHEUMarampa( View Tweet )
Nov 08, 2021
Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care
🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide
🔹🚫significant diff
🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dosehttps://t.co/AYQFXqlubl#ACR21 Abst1288 @RheumNow
Pedro Castillo @_Castillo_Pedro( View Tweet )
Nov 08, 2021
Day 2 Report from ACR21
Nov 08, 2021
This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.
Read Article
Knowledge Bowl at #ACR21
⭐️In this triad seen in TB arthritis, one can see juxta-articular osteopenia, peripheral osseous erosions, and late joint space narrowing
➡️Phermister's triad
@RheumNow
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 08, 2021
#volcosporin good ~lupus nephritis added to #MMF but underbelly - side effects like but ?less than #cyclosporin. #FDA update - ⬆️hypertension and nephrotoxicity, infection #ACR21 @RheumNow https://t.co/w5nLLSTlrB
Janet Pope @Janetbirdope( View Tweet )
Nov 08, 2021
#PJP prophylaxis debate at #lupus hub if on #prednisone + immune suppression. #SLE has ⤴️septra side effects. Don’t know right answer. NNT v NNH is unknown. I don’t use it in #SLE. @RheumNow #ACR21 8M212
Janet Pope @Janetbirdope( View Tweet )
Nov 08, 2021
ACR21 Best Abstracts - Day 2
Nov 07, 2021
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read Article
A worthwhile point:
despite historic concerns, in the modern era TNFi can used safely & well in HIV pts
18y follow-up, all pts high CD4
(their starting criteria: CD4>200, VL <60,000)
no reported opportunistic infx
good arthritis response
#ACR21 ABST0965 @RheumNow @CCalabreseDO https://t.co/5pbRg63ubr
David Liew @drdavidliew( View Tweet )
Nov 07, 2021
HZV in pts w/ #rheumatic dse by Dr CCMok et al
🔸Prevalence rates of HZV infxn (per 100py): SLE 1.7, RA 0.64, other RDs 0.76
🔸RFs assoc'd w/1st HZV infection
📌#SLE dx, serum albumin, serum creatinine; ⬆lympho/neutro ratio, CYC & Prednisolone use
@RheumNow #ACR21 abs0862 https://t.co/TXRmoBBDXK
sheila @RHEUMarampa( View Tweet )
Nov 07, 2021
Abst 0562
Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis
- Prevalence is high
- Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI)
#ACR21 @RheumNow https://t.co/UftoFllE1v
Akhil Sood MD @AkhilSoodMD( View Tweet )
Nov 07, 2021
Opening Day Report
Nov 06, 2021
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
The Year in Review
Read Article
Role of anti-CK antibodies: 👉⬆️susceptibility to severe mycobacterial dz & opportunistic infx (similar to HIV)
👉causes an indeterminate quantiferon (no response to mitogen)
👉initiated by infx➡️anti-Noc2 Ab➡️cross react with IFN➡️IFN-Ab
👉⬆️severity of #COVID19 #ACR21 1/2 https://t.co/5NHQpwQw6X
TheDaoIndex @KDAO2011( View Tweet )
Nov 06, 2021
It is always difficult to distinguish infection and disease flares in autoinflammatory syndromes = 25 pt sJIA study at #ACR21 showing serum procalcitonin levels are useful when >0.95ng/ml @StillsDis_411 @rheumnow #abst0252
Bella Mehta @bella_mehta( View Tweet )
Nov 06, 2021
@jhrheumatology Dr. Petri at #ACR21 Great Debate.
Safety issues with Voclosporin:
1) Nephrotoxicity
2) Infection
3) CV Risk Factors
4) Malignancy
5) Neurologic toxicity
6) Osteoporosis
7) Drug interactions
8) Deaths
9) Pregnancy contraindication
@RheumNow https://t.co/wjluivmKNt
Eric Dein @ericdeinmd( View Tweet )
Nov 06, 2021
RheumNow Podcast – ACR Convergence Begins (11.5.2021)
Nov 05, 2021
Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.
Read Article
Negative Concerns of Telemedicine in Rheumatology
Nov 04, 2021
Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.
Researchers surveyed a total of 1,340 (UK) patients and 111 clinicians
Read Article
Infection Rates in Psoriatic Arthritis Patients on Biologics Have Decreased
ACR
Nov 03, 2021
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.
Read Article
Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose
ACR
Nov 03, 2021
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving
Read ArticleRheumNow Podcast – Like Father, Like Daughter (10.29.2021)
Oct 29, 2021
Bad things happen when our patients go into the ICU and it's not always due to the disease. Good things happen when we rise from sitting. And guess what? Rheumatologists are setting cardiology straight about hydroxychloroquine and chloroquine. This, and a special recognition of parent-child
Read Article
Biologic Use and the Risk of Serious Infection in Psoriasis Patients
Oct 28, 2021
National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or
Read ArticleRecent Blogs
As many of you are aware, I have written and spoken on COVID-19 extensively over these past 20 months, and just last month wrote about the dangers of the delta variant. In July, things took an unexpected turn when I developed a breakthrough infection with the delta variant.
Read Post
